Last reviewed 2026-05-23 · How we verify

WB007 0.05%

Bausch & Lomb Incorporated · Phase 1 active Small molecule ✓ Verified May 2026 Quality 8/100

WB007 0.05% is a Small molecule drug developed by Bausch & Lomb Incorporated. It is currently in Phase 1 development.

WB007 is a small molecule ophthalmic solution being studied for its safety and IOP-lowering effects in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension. It is being investigated at concentrations of 0.05%, 0.15%, and 0.4% in a Phase 1/2a clinical trial.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	WB007 0.05%
Sponsor	Bausch & Lomb Incorporated
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Instillation Site Pain
Instillation Site Burn
Punctate Keratitis

Key clinical trials

Safety and IOP-Lowering Effects of WB007 (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

WB007 0.05% CI brief — competitive landscape report
WB007 0.05% updates RSS · CI watch RSS
Bausch & Lomb Incorporated portfolio CI

Frequently asked questions about WB007 0.05%

What is WB007 0.05%?

WB007 0.05% is a Small molecule drug developed by Bausch & Lomb Incorporated.

Who makes WB007 0.05%?

WB007 0.05% is developed by Bausch & Lomb Incorporated (see full Bausch & Lomb Incorporated pipeline at /company/bausch-lomb-incorporated).

What development phase is WB007 0.05% in?

WB007 0.05% is in Phase 1.

What are the side effects of WB007 0.05%?

Common side effects of WB007 0.05% include Instillation Site Pain, Instillation Site Burn, Punctate Keratitis.

Manufacturer: Bausch & Lomb Incorporated — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing